[go: up one dir, main page]

HK1070372A1 - Immunological adjuvant compounds - Google Patents

Immunological adjuvant compounds Download PDF

Info

Publication number
HK1070372A1
HK1070372A1 HK05100598.1A HK05100598A HK1070372A1 HK 1070372 A1 HK1070372 A1 HK 1070372A1 HK 05100598 A HK05100598 A HK 05100598A HK 1070372 A1 HK1070372 A1 HK 1070372A1
Authority
HK
Hong Kong
Prior art keywords
added
mixture
solution
methylene chloride
minutes
Prior art date
Application number
HK05100598.1A
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
HK1070372B (en
Inventor
Lynn D. Hawkins
Sally T. Ishizaka
Michael Lewis
Pamela Mcguinness
Anneliese Nault
Jeffrey Rose
Daniel P. Rossignol
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of HK1070372A1 publication Critical patent/HK1070372A1/en
Publication of HK1070372B publication Critical patent/HK1070372B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (9)

  1. Verbindung der Formel (I): wobei :
    R1 ausgewählt ist aus der Gruppe bestehend aus -C(O)-, -C(O) (CH2)2-C(O)- und -C(O) (CH2)4-C(O)-.
  2. Verbindung nach Anspruch 1, wobei R1 -C(O)- ist.
  3. Verbindung der Formel (II) wobei:
    R1 ausgewählt ist aus der Gruppe bestehend aus -C(O)- und -C(O) (CH2)2-C(O)-.
  4. Verbindung der Formel: oder
  5. Verbindung der Formel (V): wobei:
    R1 ausgewählt ist aus der Gruppe bestehend aus -C(O)-, -C(O) (CH2)-C(O)-, -C(O)(CH2)2-C(O)-, -C(O)(CH2)4-C(O)-, -C(O)(CH2)6-C(O)-, -C(O)(CH2)8-C(O)- und -C(O)(CH(R2))-C(O)-;
    R2
    ist;
    R3 ausgewählt ist aus der Gruppe bestehend aus -H und -(CH2)2NHBoc.
  6. Verbindung nach Anspruch 5 mit der Formel:
  7. Verbindung der Formel (VI): wobei:
    R1 ausgewählt ist aus der Gruppe bestehend aus -C(O)-, -C(O) (CH2)-C(O)- und -C(O) (CH(R2))-C(O)-;
    R2 ausgewählt ist aus der Gruppe bestehend aus (CH2)4NHBoc und
    R3 ausgewählt ist aus der Gruppe bestehend aus -(CH2)2NHBoc, -(CH2)2NH2, -(CH2)2NH(CO)(CH2)4C(O)OH.
  8. Verbindung der Formel (VI): wobei:
    R1 ist.
  9. Verbindung mit der Formel oder
HK05100598.1A 1999-02-01 2002-04-12 Immunological adjuvant compounds HK1070372B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11813199P 1999-02-01 1999-02-01
US118131P 1999-02-01
HK02102786.2A HK1043132B (en) 1999-02-01 2000-02-01 Immunological adjuvant compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK02102786.2A Addition HK1043132B (en) 1999-02-01 2000-02-01 Immunological adjuvant compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK02102786.2A Division HK1043132B (en) 1999-02-01 2000-02-01 Immunological adjuvant compounds

Publications (2)

Publication Number Publication Date
HK1070372A1 true HK1070372A1 (en) 2005-06-17
HK1070372B HK1070372B (en) 2011-04-01

Family

ID=

Also Published As

Publication number Publication date
MXPA01007760A (es) 2003-06-24
ZA200106487B (en) 2002-08-07
FI20011593L (fi) 2001-07-31
AU2004201147A1 (en) 2004-04-22
KR100711561B1 (ko) 2007-04-27
NZ513259A (en) 2004-05-28
BR0007936A (pt) 2002-04-09
ES2347428T3 (es) 2010-10-29
CA2361582A1 (en) 2000-08-03
DE60011571T2 (de) 2005-08-18
ATE471328T1 (de) 2010-07-15
IL174413A0 (en) 2009-02-11
PT1147117E (pt) 2004-10-29
WO2000044758A1 (en) 2000-08-03
HUP0105473A3 (en) 2003-11-28
NO329111B1 (no) 2010-08-30
NO20013749L (no) 2001-09-25
AU2004201147B2 (en) 2008-04-03
JP4698027B2 (ja) 2011-06-08
IL144671A0 (en) 2002-05-23
HUP0105473A2 (hu) 2002-04-29
EP1147117B1 (de) 2004-06-16
IL144671A (en) 2006-07-05
DE60044570D1 (de) 2010-07-29
DK1147117T3 (da) 2004-10-25
HU226869B1 (en) 2010-01-28
EP1147117A1 (de) 2001-10-24
ATE269341T1 (de) 2004-07-15
EP1439184A1 (de) 2004-07-21
EP1439184B1 (de) 2010-06-16
BR0007936B1 (pt) 2015-03-10
HK1043132A1 (en) 2002-09-06
ES2223464T3 (es) 2005-03-01
NO20013749D0 (no) 2001-07-31
US6290973B1 (en) 2001-09-18
CA2361582C (en) 2010-04-06
AU768574B2 (en) 2003-12-18
DE60011571D1 (de) 2004-07-22
HK1043132B (en) 2005-04-01
AU2867500A (en) 2000-08-18
BRPI0007936B8 (pt) 2021-05-25
KR20010101912A (ko) 2001-11-15
JP2002535411A (ja) 2002-10-22
FI120689B (fi) 2010-01-29

Similar Documents

Publication Publication Date Title
EP1439184B1 (de) Verbindungen mit immunologischem Adjuvanseffekt
US6551600B2 (en) Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) Immunomodulatory compounds and method of use thereof
US6835721B2 (en) Immunomodulatory compounds and methods of use thereof
US6521776B2 (en) Immunological adjuvant compounds compositions and methods of use thereof
HK1070372B (en) Immunological adjuvant compounds
AU2008202882B2 (en) Immunological adjuvant compound